{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-050363","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2023-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.163098+00:00","generated_at":"2026-06-16T12:41:03.209742+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Leap Therapeutics to present updated DKN-01/Gastric Cancer data at ASCO 2023","bullets":["Will present long-term follow-up data from Part A of Phase 2 DisTinGuish study at ASCO June 2-6, 2023.","Presentation scheduled for June 5, 2023, at 11:30 a.m. ET; abstract #4027, poster discussion session.","Study combines DKN-01 (anti-DKK1) + tislelizumab + chemo in first-line advanced GEA; Part A enrolled 25 pts.","Ongoing Part C enrolling ~160 first-line HER2- GEA pts in randomized controlled trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-050363","json":"https://secwatch.observer/filing/0001104659-23-050363.json","markdown":"https://secwatch.observer/filing/0001104659-23-050363.md","text":"https://secwatch.observer/filing/0001104659-23-050363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/0001104659-23-050363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465923050363/tm2313816d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T12:41:03.209742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}